ME02230B - Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink - Google Patents

Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink

Info

Publication number
ME02230B
ME02230B MEP-2015-149A MEP14915A ME02230B ME 02230 B ME02230 B ME 02230B ME P14915 A MEP14915 A ME P14915A ME 02230 B ME02230 B ME 02230B
Authority
ME
Montenegro
Prior art keywords
heteroaryl
aryl
aliphatic
acyl
heterocyclic
Prior art date
Application number
MEP-2015-149A
Other languages
English (en)
Inventor
Xiong Cai
Haixiao Zhai
Cheng-Jung Lai
Changgeng Qian
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of ME02230B publication Critical patent/ME02230B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (1)

1. Jedinjenje koje je predstavljeno formulom (IV), (V), (VI) ili (VII); ili njegova farmaceutski prihvatljiva so, gde ---------- predstavlja jednostruku ili dvostruku vezu; B je prav ili razgranati, alkil, alkenil, alkinil, arilalkil, arilalkenil, arilalkinil, heteroarilalkil, heteroarilalkenil, heteroarilalkinil, heterociklilalkil, heterociklilalkenil, heterociklilalkinil, aril, heteroaril, heterociklil, cikloalkil, cikloalkenil, alkilarilalkil, alkilarilalkenil, alkilarilalkinil, alkenilarilalkil, alkenilarilalkenil, alkenilarilalkinil, alkinilarilalkil, alkinilarilalkenil, alkinilarilalkinil, alkilheteroarilalkil, alkilheteroarilalkenil, alkilheteroarilalkinil, alkenilheteroarilalkil, alkenilheteroarilalkenil, alkenilheteroarilalkinil, alkinilheteroarilalkil, alkinilheteroarilalkenil, alkinilheteroarilalkinil, alkilheterociklilalkil, alkilheterociklilalkenil, alkilheterociklilalkinil, alkenilheterociklilalkil, alkenilheterociklilalkenil, alkenilheterociklilalkinil, alkinilheterociklilalkil, alkinilheterociklilalkenil, alkinilheterociklilalkinil, alkilaril, alkenilaril, alkinilaril, alkilheteroaril, alkenilheteroaril, ili alkinilheteroaril, kod kog jedan ili više metilena može da se prekine ili završi putem O, S, S(O), SO2, N(R8), C(O), arila, heteroarila, ili heterocillika;s je 1; q i r su svaki 0; n je 0, 1, 2, 3 ili 4; p je 0, 1 ili 2; G1 je CHR1, S, O, NR10 ili NS(O)2R10;G2 je supstituisani ili nesupstituisani arili ili supstituisani ili nesupstituisani heteroaril; svaki R1 i R2 se nezavisno bira iz hidroksi, amino, halogen, alkoksi, alkilamino, dialkilamino, CF3, CN, NO2, sulfonil, acil, alifatik, aril, heteroaril i heterociklik;svaki R8 je nezavisno vodonik, acili ili alifatik; R10 se bira iz vodonika, hidroksi, amino, alkoksi, alkilamino, dialkilamino, sulfonil, acil, alifatik, aril, heteroaril, i heterociklik;m je 0, 1, 2 ili 3; G4 je S ili O;svaki R3 je nezavisno izabran iz hidroksi, amino, halogen, alkoksi, alkilamino, dialkilamino, CF3, CN, NO2, sulfonil, acil, alifatik, supstituisani alifatik, aril, heteroaril, i heterociklik; i Cis gde se R33 bira iz vodonika i C1-C8 alkila.
MEP-2015-149A 2009-01-08 2010-01-08 Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink ME02230B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14327109P 2009-01-08 2009-01-08
US17258009P 2009-04-24 2009-04-24
EP10729566.9A EP2385832B1 (en) 2009-01-08 2010-01-08 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
PCT/US2010/020495 WO2010080996A1 (en) 2009-01-08 2010-01-08 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Publications (1)

Publication Number Publication Date
ME02230B true ME02230B (me) 2016-02-20

Family

ID=42316830

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-149A ME02230B (me) 2009-01-08 2010-01-08 Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink

Country Status (25)

Country Link
US (11) US8367663B2 (me)
EP (1) EP2385832B1 (me)
JP (3) JP5452617B2 (me)
KR (2) KR20140094590A (me)
CN (1) CN102341108B (me)
AU (1) AU2010203512C1 (me)
BR (1) BRPI1004899B8 (me)
CA (1) CA2749228C (me)
CY (1) CY1116797T1 (me)
DK (1) DK2385832T3 (me)
EA (1) EA024252B1 (me)
ES (1) ES2550032T3 (me)
HR (1) HRP20150947T1 (me)
HU (1) HUE027615T2 (me)
IL (2) IL213976A (me)
ME (1) ME02230B (me)
MX (1) MX2011007326A (me)
PL (1) PL2385832T3 (me)
PT (1) PT2385832E (me)
RS (1) RS54230B1 (me)
SG (2) SG172908A1 (me)
SI (1) SI2385832T1 (me)
SM (1) SMT201500226B (me)
TW (1) TWI558710B (me)
WO (1) WO2010080996A1 (me)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
JP2013504325A (ja) * 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
EP2557923A4 (en) * 2010-04-16 2013-10-23 Curis Inc TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS
EP2615092B1 (en) * 2010-09-10 2015-08-26 Hangzhou Bensheng Pharmaceutical Co., Ltd. Heterocyclic amino berbamine derivatives, preparation method and use thereof
NZ710405A (en) * 2010-11-16 2017-04-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
PL2651417T3 (pl) 2010-12-16 2017-08-31 Calchan Limited Pochodne pirolopirymidyny hamujące ASK1
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
WO2012103524A2 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinasa as anti- viral agents
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
HUE028910T2 (en) 2011-04-01 2017-01-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
WO2013078126A1 (en) * 2011-11-23 2013-05-30 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
EP3013810A1 (en) 2013-06-24 2016-05-04 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
ES2929576T3 (es) 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
EP3055299B1 (en) 2013-10-10 2021-01-06 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
KR20160092018A (ko) 2013-12-03 2016-08-03 에이스틸론 파마수티컬스 인코포레이티드 히스톤 탈아세틸화효소 저해제 및 면역조절 약물의 조합
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
AU2015288060A1 (en) 2014-07-07 2017-02-09 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CN104292242B (zh) * 2014-09-18 2017-05-17 广州必贝特医药技术有限公司 噻吩嘧啶类化合物和制剂及其制备方法和应用
AU2015356779A1 (en) 2014-12-05 2017-07-13 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
MY188946A (en) * 2014-12-11 2022-01-14 Natco Pharma Ltd 7-(morpholinyl)-2-(n-piperazinyl methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
WO2016169417A1 (zh) * 2015-04-21 2016-10-27 成都金瑞长青生物科技有限公司 嘌呤基-n-羟基嘧啶甲酰胺衍生物及其制备方法和用途
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CN105037345B (zh) * 2015-06-09 2019-01-25 天津渤海职业技术学院 抗肿瘤化合物、其制备方法和用途
WO2017090058A1 (en) * 2015-11-23 2017-06-01 Council Of Scientific & Industrial Research Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP3445364A4 (en) 2016-04-19 2019-11-27 Acetylon Pharmaceuticals, Inc. HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
RU2019108280A (ru) 2016-08-24 2020-09-25 Аркьюл, Инк. Аминопирролопиримидиноновые соединения и способы их применения
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2017362350B2 (en) * 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
CN108623491B (zh) * 2017-03-24 2020-12-22 联化科技股份有限公司 一种卤代苯甲酰胺化合物的制备方法
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
WO2020055840A1 (en) 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EA202191422A1 (ru) 2018-11-21 2021-10-21 Кейс Вестерн Ризерв Юниверсити Композиции и способы модулирования активности короткоцепочечной дегидрогеназы
MX2021009142A (es) * 2019-02-06 2021-10-13 Venthera Inc Inhibidores topicos de fosfoinositol 3-cinasas.
AR120173A1 (es) * 2019-10-09 2022-02-02 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 核内受容体に対して活性の化合物
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CN115135659B (zh) * 2021-01-15 2024-03-12 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
CN117203212A (zh) * 2021-03-29 2023-12-08 株式会社钟化 (2-甲基嘧啶-5-基)硼酸衍生物的制造方法
CN113754680B (zh) * 2021-09-28 2022-07-22 云白药征武科技(上海)有限公司 一种α氟代酰基哌嗪衍生物及其制备和应用
JP2024533630A (ja) * 2021-09-30 2024-09-12 ハンミ ファーマシューティカルズ カンパニー リミテッド ＰＩＫｆｙｖｅキナーゼ阻害剤
CN117865979A (zh) * 2024-01-04 2024-04-12 广州必贝特医药股份有限公司 噻吩嘧啶类化合物的晶型及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
AU6410699A (en) * 1998-10-13 2000-05-01 Chris Cheah Method and system for controlled distribution of information over a network
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
EP1485348B1 (en) 2002-03-13 2008-06-11 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
KR101074462B1 (ko) * 2003-01-29 2011-10-18 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 화합물 및 그 용도
JP5213229B2 (ja) * 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
US7218492B2 (en) * 2004-09-17 2007-05-15 Electronic Polymers, Inc. Devices and systems for electrostatic discharge suppression
EP1806347A4 (en) 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
CA2605272C (en) 2005-05-18 2013-12-10 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US7731753B2 (en) * 2005-09-01 2010-06-08 Spinal Kinetics, Inc. Prosthetic intervertebral discs
AU2006306462B2 (en) * 2005-10-24 2012-07-26 Biomet 3I, Llc Methods for manufacturing dental implant components
JP2007151829A (ja) * 2005-12-05 2007-06-21 Bridgestone Sports Co Ltd ゴルフクラブヘッド
EP1979328B1 (en) 2006-01-19 2012-12-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP1981871B1 (en) 2006-01-19 2011-12-28 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
EP2041139B1 (en) * 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Pharmaceutical compounds
MX2008013582A (es) 2006-04-26 2009-01-19 Hoffmann La Roche Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033744A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Dna methyl transferase inhibitors containing a zinc binding moiety
MX2009002585A (es) * 2006-09-11 2009-08-24 Curis Inc Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc.
WO2008033747A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
EP2061469B8 (en) * 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
WO2008033746A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2008033745A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
CN103275067B (zh) 2006-10-28 2015-09-02 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
KR101507182B1 (ko) 2006-12-07 2015-03-30 제넨테크, 인크. 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
TWI499420B (zh) * 2006-12-07 2015-09-11 Hoffmann La Roche 肌醇磷脂３-激酶抑制劑化合物及使用方法
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
JP2010522163A (ja) 2007-03-20 2010-07-01 キュリス，インコーポレイテッド 亜鉛結合部位を含むＲａｆキナーゼインヒビター
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
AU2008312631A1 (en) * 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009058895A1 (en) 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
AU2010224125B2 (en) 2009-03-12 2015-05-14 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
ES2609767T3 (es) 2009-10-12 2017-04-24 F. Hoffmann-La Roche Ag Combinaciones de un inhibidor de PI3K y un inhibidor de MEK
EP2557923A4 (en) * 2010-04-16 2013-10-23 Curis Inc TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS
HUE028910T2 (en) * 2011-04-01 2017-01-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
SI2385832T1 (sl) 2015-10-30
EA201101053A1 (ru) 2012-02-28
US10894795B2 (en) 2021-01-19
US11597732B2 (en) 2023-03-07
AU2010203512C1 (en) 2013-10-17
MX2011007326A (es) 2011-10-19
CA2749228C (en) 2016-05-17
KR101430424B1 (ko) 2014-08-14
US10676482B2 (en) 2020-06-09
RS54230B1 (sr) 2015-12-31
US20250230169A1 (en) 2025-07-17
US20230227467A1 (en) 2023-07-20
AU2010203512A1 (en) 2011-08-11
WO2010080996A1 (en) 2010-07-15
US9725461B2 (en) 2017-08-08
ES2550032T3 (es) 2015-11-04
KR20140094590A (ko) 2014-07-30
BRPI1004899A2 (pt) 2016-04-05
US20210214370A1 (en) 2021-07-15
IL213976A0 (en) 2011-08-31
JP2015187145A (ja) 2015-10-29
EP2385832B1 (en) 2015-07-15
EP2385832A4 (en) 2012-07-25
US20190352310A1 (en) 2019-11-21
KR20110112404A (ko) 2011-10-12
HRP20150947T1 (hr) 2015-10-09
US20220402934A1 (en) 2022-12-22
US10336770B2 (en) 2019-07-02
JP2012514650A (ja) 2012-06-28
HUE027615T2 (en) 2016-10-28
IL213976A (en) 2015-03-31
TW201030009A (en) 2010-08-16
BRPI1004899B8 (pt) 2021-05-25
US20100222343A1 (en) 2010-09-02
US20120088764A1 (en) 2012-04-12
EA024252B1 (ru) 2016-08-31
AU2010203512B2 (en) 2013-03-14
US20170362251A1 (en) 2017-12-21
SG196815A1 (en) 2014-02-13
US8461157B2 (en) 2013-06-11
JP5452617B2 (ja) 2014-03-26
CN102341108A (zh) 2012-02-01
CY1116797T1 (el) 2018-03-07
PL2385832T3 (pl) 2016-01-29
BRPI1004899B1 (pt) 2020-08-18
US20200339593A1 (en) 2020-10-29
SMT201500226B (it) 2015-10-30
SG172908A1 (en) 2011-08-29
HK1164113A1 (en) 2012-09-21
US20140155595A1 (en) 2014-06-05
JP2014058571A (ja) 2014-04-03
JP5762520B2 (ja) 2015-08-12
US11261195B2 (en) 2022-03-01
US20150203509A1 (en) 2015-07-23
TWI558710B (zh) 2016-11-21
US8367663B2 (en) 2013-02-05
PT2385832E (pt) 2015-11-02
US8906909B2 (en) 2014-12-09
CN102341108B (zh) 2015-05-27
IL237727A0 (en) 2015-05-31
EP2385832A1 (en) 2011-11-16
CA2749228A1 (en) 2010-07-15
DK2385832T3 (en) 2015-09-21

Similar Documents

Publication Publication Date Title
ME02230B (me) Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
JP2010502744A5 (me)
JP2010502743A5 (me)
JP2010522163A5 (me)
JP2010502741A5 (me)
JP2010502742A5 (me)
JP6148192B2 (ja) アシストスーツ
TWI632348B (zh) Environmental light filtering circuit, optical sensor and photoelectric detecting device using same
TWI600584B (zh) 具有接觸部件之前變速器
PT2248442E (pt) Conjunto estabilizador de suporte amovível
EP3057142A3 (en) Bi-directional reflective optical sensor module
AU2007296740A1 (en) Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
PE20110804A1 (es) Compuestos novedosos como ligandos de receptores de cannabinoides
RU2016134035A (ru) УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА
JP2011525482A5 (me)
CN102792813B (zh) 用于穴盘苗移栽的自动取喂苗机构
RU2012134446A (ru) Система позиционирования по меньшей мере одного гибкого трубчатого элемента, соединенного с чашеобразным элементом
JPWO2023280190A5 (me)
JP2009518802A5 (me)
JP2010520194A5 (me)
TR201718650T3 (tr) Bir taşıyıcı içeren bir çamaşır kurutucu.
CN112557866A (zh) 一种发光二极管批量质量检测设备
CN201782519U (zh) 简易折叠式衣架
JP2020204046A5 (me)
TWM380331U (en) Automatic dragging gripper